CR20230263A - Anticuerpos anti-hla-g y uso de estos - Google Patents

Anticuerpos anti-hla-g y uso de estos

Info

Publication number
CR20230263A
CR20230263A CR20230263A CR20230263A CR20230263A CR 20230263 A CR20230263 A CR 20230263A CR 20230263 A CR20230263 A CR 20230263A CR 20230263 A CR20230263 A CR 20230263A CR 20230263 A CR20230263 A CR 20230263A
Authority
CR
Costa Rica
Prior art keywords
hla
antibodies
antibody
variants
glycosylation
Prior art date
Application number
CR20230263A
Other languages
English (en)
Inventor
Thomas Weindl
Meher Majety
Ekkehard Moessner
Alexander Bujotzek
Carina Hage
Thomas Hofer
Gutierrez Cirlos Alejandro Carpy
Christian Spick
Anne Freimoser-Grundschober
Silke Kirchner
Georg Tiefenthaler
Christiane Neumann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230263A publication Critical patent/CR20230263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a HLA-G humano, anticuerpos multiespecíficos de este, su preparación, formulaciones y métodos de uso de estos.
CR20230263A 2020-12-17 2021-12-15 Anticuerpos anti-hla-g y uso de estos CR20230263A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20214951 2020-12-17
EP21203272 2021-10-18
PCT/EP2021/085810 WO2022129120A1 (en) 2020-12-17 2021-12-15 Anti-hla-g antibodies and use thereof

Publications (1)

Publication Number Publication Date
CR20230263A true CR20230263A (es) 2023-08-21

Family

ID=79288043

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230263A CR20230263A (es) 2020-12-17 2021-12-15 Anticuerpos anti-hla-g y uso de estos

Country Status (13)

Country Link
US (2) US20220213199A1 (es)
EP (1) EP4263609A1 (es)
JP (3) JP7326584B2 (es)
KR (1) KR20230120665A (es)
AU (1) AU2021399841A1 (es)
CA (1) CA3204702A1 (es)
CO (1) CO2023008643A2 (es)
CR (1) CR20230263A (es)
IL (1) IL303656A (es)
MX (1) MX2023007133A (es)
PE (1) PE20240819A1 (es)
TW (2) TWI845353B (es)
WO (1) WO2022129120A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
SG11202102859TA (en) 2018-12-21 2021-04-29 Hoffmann La Roche Antibodies binding to cd3
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
WO2022129120A1 (en) * 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
IL322890A (en) * 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
WO2024188966A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
EP4793288A1 (en) * 2023-10-12 2026-08-19 Imbiologics Corp. Antibody specifically binding to hla-g, and use thereof
GB202319122D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211999B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6790638B1 (en) 1998-02-20 2004-09-14 Commissariat A L'energie Atomique Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
ES2267275T3 (es) 1998-07-10 2007-03-01 Connex Gmbh Reactivo inmunologico que interacciona especificamente con el dominio extracelular de la cadena zeta humana.
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2002022784A2 (en) 2000-09-15 2002-03-21 University Of Kansas Medical Center Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
AU2002228745A1 (en) 2000-10-23 2002-05-06 Rajagopalan, Sumati Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2003031376A1 (en) 2001-10-12 2003-04-17 Aventis Pharmaceuticals Inc. Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
WO2005042693A2 (ja) 2003-11-04 2005-05-12 The Animal Engineering Research Institute Ｈｌａ−ｅキメラ分子
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN1312182C (zh) 2004-10-26 2007-04-25 四川新创生物科技有限公司 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2264067A1 (en) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 multimers and pharmaceutical uses thereof
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US9359424B2 (en) 2009-06-25 2016-06-07 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of HLA-G including alpha1-alpha3 monomers and pharmaceutical uses thereof
CN101967191A (zh) 2009-07-28 2011-02-09 广州天美生物技术有限公司 Hla-g抗体制备方法及其在医学中的应用
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013007069A2 (pt) 2010-09-29 2016-09-13 Uti Limited Partnership métodos para tratar doença autoimune usando nanoesferas biocompatíveis e bioabsorvíveis
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
KR101886983B1 (ko) 2011-08-23 2018-08-08 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2013164325A1 (en) 2012-05-02 2013-11-07 F. Hoffmann-La Roche Ag Multispecific antigen binding proteins
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
MX2014015557A (es) 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
RU2015105561A (ru) 2012-08-09 2016-09-27 Ф. Хоффманн-Ля Рош Аг Замещенные гетероазепиноны
EP2730588A1 (en) 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
BR122020023058B1 (pt) * 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos
CN110437337B (zh) 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
CN106795220A (zh) 2013-10-30 2017-05-31 建新公司 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
BR112016011027A2 (pt) 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
ES2765710T3 (es) 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
JP6829194B2 (ja) 2014-10-24 2021-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
SG11201703750XA (en) 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
JP6727224B2 (ja) 2015-03-02 2020-07-22 アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ 新生物疾患および／または感染性疾患の治療にとって有用な二環式テトラヒドロチアゼピン誘導体
US20190119385A1 (en) 2015-03-27 2019-04-25 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
PE20181349A1 (es) 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
EP4015533A1 (en) 2015-10-29 2022-06-22 F. Hoffmann-La Roche AG Anti-variant fc-region antibodies and methods of use
CA3025681A1 (en) 2016-06-03 2017-12-07 Invectys Anti hla-g specific antibodies
TW201811752A (zh) 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JP6829357B2 (ja) 2017-03-17 2021-02-10 住友ベークライト株式会社 抗体の糖鎖検出法
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
SG11202102859TA (en) 2018-12-21 2021-04-29 Hoffmann La Roche Antibodies binding to cd3
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
JP2022543553A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
CA3176552A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Immune activating fc domain binding molecules
AR122656A1 (es) 2020-06-19 2022-09-28 Hoffmann La Roche Anticuerpos que se unen a cd3 / folr1
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
MX2023002947A (es) 2020-09-11 2023-06-06 Univ California Composiciones y métodos para el tratamiento de distrofias musculares.
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
MX2023009086A (es) 2021-02-12 2023-08-08 Relay Therapeutics Inc Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos.

Also Published As

Publication number Publication date
JP2025037987A (ja) 2025-03-18
AU2021399841A9 (en) 2024-02-08
TW202233686A (zh) 2022-09-01
WO2022129120A1 (en) 2022-06-23
CO2023008643A2 (es) 2023-08-09
US12466889B2 (en) 2025-11-11
JP2023156273A (ja) 2023-10-24
MX2023007133A (es) 2023-06-27
JP2023510669A (ja) 2023-03-15
US20220213199A1 (en) 2022-07-07
AU2021399841A1 (en) 2023-07-06
TWI808571B (zh) 2023-07-11
PE20240819A1 (es) 2024-04-18
JP7895910B2 (ja) 2026-07-28
EP4263609A1 (en) 2023-10-25
US20230159642A1 (en) 2023-05-25
WO2022129120A9 (en) 2023-06-08
TW202342543A (zh) 2023-11-01
TWI845353B (zh) 2024-06-11
KR20230120665A (ko) 2023-08-17
CA3204702A1 (en) 2022-06-23
IL303656A (en) 2023-08-01
JP7326584B2 (ja) 2023-08-15

Similar Documents

Publication Publication Date Title
MX2023007133A (es) Anticuerpos anti-hla-g y uso de estos.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2012145507A3 (en) Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
PH12020550055A1 (en) Antibodies that bind egfr and cmet
EP4295918A3 (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
RU2011116112A (ru) Биспецифические анти-egfr/анти-igf-1r антитела
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP4483895A3 (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
WO2021022304A3 (en) Bispecific anti lrrc15 and cd3epsilon antibodies
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ739028A (en) Humanized or chimeric cd3 antibodies
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
WO2012143524A3 (en) Bispecific antibodies against her2 and cd3
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
CL2020002539A1 (es) Anticuerpos multiespecíficos anti-hla-g y utilización de los mismos
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
CO2022000404A2 (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden